Video Experimental Relacionado
Updated: Sep 8, 2025
05:59
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
2.5K
Manejo farmacológico del insomnio en la enfermedad de Parkinson
Karolina Popławska Domaszewicz1, Vinod Metta2, Rosabel Chen3
1Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland; Parkinson Foundation Centre of Excellence, King's College Hospital London, United Kingdom.
Sleep medicine clinics
|September 5, 2025
Resumen
La disfunción del sueño es común en la enfermedad de Parkinson (EP). Las terapias dopaminérgicas continuas, como las infusiones de rotigotina o levodopa, son prometedoras para mejorar el insomnio de mantenimiento del sueño en pacientes con EP.
Área de la Ciencia:
- Neurología
- Medicina del sueño
- Farmacología
Sus antecedentes:
- La disfunción del sueño afecta hasta al 90% de los pacientes con enfermedad de Parkinson (EP).
- El insomnio, particularmente el sueño fragmentado, es un síntoma prevalente y desafiante en la EP.
- Las estrategias de tratamiento actuales para los trastornos del sueño en la EP ofrecen una eficacia limitada.
Objetivo del estudio:
- Revisar la eficacia de los sistemas de administración de fármacos dopaminérgicos continuos para el tratamiento de la disfunción del sueño en la enfermedad de Parkinson.
- Evaluar las opciones de tratamiento no oral para el insomnio de mantenimiento del sueño en pacientes con EP.
- Para discutir los enfoques farmacológicos actuales para el insomnio en la enfermedad de Parkinson.
Principales métodos:
- Revisión de la literatura de estudios sobre la disfunción del sueño en la enfermedad de Parkinson.
- Análisis de los datos sobre los sistemas de administración continua de fármacos, incluidas las vías transdérmica, subcutánea e intrayeccional.
- Examen de los tratamientos farmacológicos para el insomnio y las enfermedades concomitantes.
Principales resultados:
- Las terapias dopaminérgicas continuas, como la rotigotina transdérmica y la infusión subcutánea de apomorfina, demuestran eficacia para mejorar el insomnio de mantenimiento del sueño.
- Las infusiones de levodopa inyectables o subcutáneas muestran una eficacia considerable en el alivio del insomnio en pacientes con EP.
- El tratamiento farmacológico para el insomnio con inicio de sueño sigue siendo subóptimo, con opciones que incluyen el uso cauteloso de sedantes/hipnóticos y el tratamiento de factores comórbidos.
Conclusiones:
- Las estrategias de administración continua de medicamentos representan una vía terapéutica prometedora para el mantenimiento del insomnio en la enfermedad de Parkinson.
- Se necesitan más investigaciones para optimizar las intervenciones farmacológicas para el insomnio de inicio del sueño en la EP.
- La gestión integral que aborde tanto los síntomas motores como los no motores es crucial para mejorar la calidad del sueño en la EP.
Palabras clave:
Insomnio de mantenimientoEl inicio del insomnioLa enfermedad de ParkinsonEl sueño.Cuidados escalonadosMás Videos Relacionados
Videos de Conceptos Relacionados
01:19Management of Insomnia
319
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
319
01:24Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
236
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
236
01:15Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
01:27Insomnia
123
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
123
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
123
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
123